HIGHLIGHTS
- who: Sahar Roshanbin et al. from the Department of Public Health and Caring Sciences, Uppsala University, , Uppsala, SwedenKrembil Brain Institute, University Health Network, Toronto, ON M T , Canada have published the article: Reduction of SYN Pathology in a Mouse Model of PD Using a Brain-Penetrating Bispecific Antibody, in the Journal: Pharmaceutics 2022, 1412 of /2022/
- what: As the main purpose of the BBB is to maintain the microenvironment in the brain, a noninvasive approach to circumvent the BBB is preferred. Taken together, this study shows that RMT greatly enhances the brain distribution of a . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.